前列腺癌男性患者停用地舒单抗后的骨密度变化
这项回顾性队列研究纳入50例非转移性前列腺癌男性患者,这些患者在接受放疗和雄激素剥夺治疗3年、地舒单抗平均5年后停药。未用唑来膦酸者腰椎、全髋和股骨颈骨密度分别下降4.9%、1.9%和2.4%;骨量减少者使用唑来膦酸可防止骨丢失。
要点
- 停用地舒单抗后未用唑来膦酸者腰椎骨密度下降4.9%。
- 唑来膦酸组骨密度在脊柱和股骨颈维持稳定。
- 1例未用唑来膦酸者停药后发生多次脆性椎体骨折。
核心结论
- 在非转移性前列腺癌男性中,停止雄激素剥夺治疗后停用地舒单抗导致平均2-5%的骨丢失,唑来膦酸可预防骨量减少者的骨丢失。
研究设计与样本
- 回顾性队列研究,基于2018年6月1日至2021年6月1日期间奥胡斯大学医院泌尿科转诊至内分泌科患者的病历资料,纳入50例非转移性前列腺癌男性。
主要发现
- 地舒单抗平均治疗 duration 为5±0.1年。
- 未用唑来膦酸组(n=24)第一次与第二次DXA之间腰椎、全髋和股骨颈骨密度分别下降4.9±4.2%、1.9±3.5%和2.4±3.6%(所有p≤0.01)。
- 使用唑来膦酸组(n=9)平均16个月后脊柱和股骨颈骨密度维持稳定。
- 1例未接受唑来膦酸的患者在地舒单抗停药后发生多次脆性椎体骨折。
关键数值与推荐
- 第一次DXA时腰椎或全髋骨密度T值≤-1的患者接受唑来膦酸治疗。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
UNLABELLED: In patients with non-metastatic prostate cancer, treated with radiation therapy and androgen deprivation therapy for 3 years and DMAB on average for 5 years, BMD was in the normal or osteopenic range. Discontinuation of DMAB led to a bone loss of 2-5%. In men with osteopenia, the bone loss was prevented by zoledronate. PURPOSE: Patients with prostate cancer receiving androgen deprivation therapy (ADT) are treated with denosumab (DMAB) to prevent fractures and preserve bone mass. We wanted to investigate the change in BMD in men with non-metastatic prostate cancer discontinuing DMAB. METHODS: We conducted a retrospective cohort study based on medical records from patients referred to the Department of Endocrinology from the Department of Urology, Aarhus University Hospital between June 1, 2018, and June 1, 2021. We retrieved information on biochemistry and DXA performed 0-6 months after the last DMAB injection and a second DXA performed approximately 12 months after the first. In case of a BMD T-score ≤ - 1 at the lumbar spine or total hip at the first DXA, the patients were treated with zoledronate. The primary endpoint was change in lumbar spine BMD. RESULTS: We included 50 patients with non-metastatic prostate cancer. The mean DMAB treatment duration was 5 ± 0.1 years. Among the patients treated with zoledronate (n = 9), BMD was maintained at the spine and femoral neck after a mean of 16 months. We found a significant decrease in BMD; - 4.9 ± 4.2%, - 1.9 ± 3.5%, and - 2.4 ± 3.6% at the spine, total hip, and femoral neck between the first and second DXA in the patients not treated with zoledronate (n = 24) (p ≤ 0.01 for all). One patient who did not receive ZOL sustained multiple fragility vertebral fractures after DMAB discontinuation. CONCLUSION: In men with non-metastatic prostate cancer, discontinuation of DMAB after stopping ADT led to an average bone loss of 2-5%. Zoledronate prevented bone loss in men with osteopenia.
引用
- Sølling AS, Harsløf T, Brockstedt HK, et al. Discontinuation of denosumab in men with prostate cancer. Osteoporos Int. 2022. PMID: 36402867. doi:10.1007/s00198-022-06610-9
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。